Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
IL21R
REST API REST API
Homo sapiens
IL21R is differentially expressed in 235 experiments: 76 organism parts: spleen, thymus, ... (74 more);, 186 disease states: normal, prostate carcinoma, ... (184 more);, 98 cell types 444 cell lines 34 compound treatments and 72 other conditions.
Synonyms CD360
Orthologs Il21r (Mus musculus)   il21rl (Danio rerio)   il21r (Danio rerio)   IL21R (Gallus gallus)   IL21R (Bos taurus)   Il21r (Rattus norvegicus)   il21r (Xenopus laevis)   IL21R (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytokine-mediated signaling pathway, membrane, receptor activity, integral to membrane, cytokine receptor activity, natural killer cell activation, interleukin-21 receptor activity
UniProt Accession Q9HBE5
Gene-Disease Assocation IgE RESPONSIVENESS, ATOPIC; IGER
Search EB-eye ENSG00000103522
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-2450, ... (30 experiments)

Factor Value U/D Experiments
MCF-7
2
E-GEOD-20081, E-GEOD-19639
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HL-60
2
E-GEOD-24147, E-MTAB-37
HT1080
2
E-GEOD-20089, E-MTAB-37
HepG2
2
E-MTAB-37, E-GEOD-21154
K562
2
E-GEOD-24147, E-MTAB-37
438 more value(s).


Cell type

studied in E-MEXP-1242, E-TABM-40, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, ... (45 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
CD8+ T cell
2
E-AFMX-5, E-TABM-145
CD4+ T cell
1
2
E-GEOD-16190, E-AFMX-5, E-TABM-145
double positive thymocyte
1
E-GEOD-1460
92 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-16363, E-GEOD-9692, E-MTAB-62, ... (41 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
3
E-MTAB-62, E-MEXP-2034, E-MTAB-37, E-GEOD-7307
Raji Burkitt's lymphoma
2
E-AFMX-5, E-TABM-145
adenocarcinoma
2
E-MTAB-37, E-MTAB-62
chronic lymphocytic leukemia
2
E-MTAB-37, E-GEOD-6691
colon carcinoma
2
E-MTAB-37, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
180 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-3720, E-GEOD-15811, E-GEOD-5099, E-MEXP-1958, ... (17 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
interleukin-4 (Homo sapiens) + anti-CD40
1
E-GEOD-7307
hydrogen peroxide
1
E-GEOD-5339
no estradiol
1
E-GEOD-20081
TTA
1
E-MEXP-2590
28 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-1140, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-577, E-GEOD-21138, E-GEOD-19665

Environmental stress
studied in E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-20847, E-MEXP-2340, E-MEXP-563

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-17476, E-MEXP-421, E-GEOD-22593, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-MEXP-2657, E-TABM-127, E-GEOD-22278, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-MEXP-1648, E-GEOD-3606, ... (30 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (6 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19246

Qpcr egfr dct
studied in E-GEOD-5851

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19743, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

Strain or line
studied in E-TABM-125

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-MEXP-973, E-GEOD-19246, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-TABM-43, E-GEOD-4922

Tumor size
studied in E-GEOD-3494

Processing time: 0.306 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM